SCHEMBL29609676

SCHEMBL29609676

Nc1cccc(N2CCC[C@@H](O)C2)n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMPD3 Q9NY59 4/20 0.55
▸ PIM1 P11309 6/20 0.46
▸ PIM3 Q86V86 2/20 0.46
▸ PIM2 Q9P1W9 2/20 0.46
▸ GRIN2D O15399 1/20 0.46
▸ GRIN3B O60391 1/20 0.46
▸ GRIN1 Q05586 1/20 0.46
▸ GRIN2A Q12879 1/20 0.46
▸ GRIN2B Q13224 1/20 0.46
▸ GRIN2C Q14957 1/20 0.46
▸ GRIN3A Q8TCU5 1/20 0.46
▸ SMARCA2 P51531 1/20 0.44
▸ SMARCA4 P51532 1/20 0.44
▸ PBRM1 Q86U86 1/20 0.44
▸ PRKCQ Q04759 1/20 0.43
▸ CCNE2 O96020 1/20 0.42
▸ CCNE1 P24864 1/20 0.42
▸ CDK2 P24941 1/20 0.42
▸ IKBKB O14920 1/20 0.42
▸ IDH2 P48735 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22122617 1.00 SMPD3 (0.55) SMPD3PIM1PIM3PIM2GRIN2D
SCHEMBL22163217 1.00 SMPD3 (0.55) SMPD3PIM1PIM3PIM2GRIN2D
SCHEMBL22122618 1.00 SMPD3 (0.55) SMPD3PIM1PIM3PIM2GRIN2D
SCHEMBL22163201 0.91 GRIN2D (0.48) SMPD3PIM1PIM3PIM2GRIN2D
SCHEMBL15652231 0.91 GRIN2D (0.48) SMPD3PIM1PIM3PIM2GRIN2D
SCHEMBL20689452 0.84 GRIN2B (0.49) SMPD3PIM1PIM3PIM2GRIN2D
SCHEMBL23247014 0.82 SMPD3 (0.49) SMPD3PIM1PIM3PIM2CCNE2
SCHEMBL29764542 0.82 SMPD3 (0.49) SMPD3PIM1PIM3PIM2CCNE2
SCHEMBL23247423 0.82 SMPD3 (0.49) SMPD3PIM1PIM3PIM2CCNE2
SCHEMBL25240736 0.81 SMPD3 (0.49) SMPD3PIM1PIM3PIM2SMARCA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12459932-B2 KIF18A inhibitors AMGEN INC. (US) 2025-11-04 — — US disclosed
US-20220073504-A1 KIF18A INHIBITORS AMGEN INC. (US) 2022-03-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220073504-A1 KIF18A INHIBITORS KIF18A, KIF18B, KIF15 SMPD3 2890/4885PIM1 3375/4885PIM3 3379/4885
US-12459932-B2 KIF18A inhibitors KIF18A, KIF18B, KIF15 SMPD3 2890/4885PIM1 3375/4885PIM3 3379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback